179 related articles for article (PubMed ID: 15251123)
1. The Fas signalling pathway and its role in the pathogenesis of cancer.
Houston A; O'Connell J
Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
[TBL] [Abstract][Full Text] [Related]
2. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
O'Connell J
Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
[TBL] [Abstract][Full Text] [Related]
3. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.
Walker PR; Saas P; Dietrich PY
J Immunol; 1997 May; 158(10):4521-4. PubMed ID: 9144461
[TBL] [Abstract][Full Text] [Related]
4. Fas and Fas ligand interactions in malignant disease.
Owen-Schaub L; Chan H; Cusack JC; Roth J; Hill LL
Int J Oncol; 2000 Jul; 17(1):5-12. PubMed ID: 10853011
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
6. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line.
Chang JS; Hsu YL; Kuo PL; Chiang LC; Lin CC
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):716-22. PubMed ID: 15554914
[TBL] [Abstract][Full Text] [Related]
8. The role of Fas and FasL as mediators of anticancer chemotherapy.
Poulaki V; Mitsiades CS; Mitsiades N
Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of bovine ovarian surface epithelial cells by Fas antigen/Fas ligand signaling.
Margalit KA; Cowan RG; Harman RM; Quirk SM
Reproduction; 2005 Nov; 130(5):751-8. PubMed ID: 16264104
[TBL] [Abstract][Full Text] [Related]
10. Fas/Fas ligand on the road: an apoptotic pathway common to AIDS, autoimmunity, lymphoproliferation and transplantation.
Famularo G; Nucera E; Marcellini S; De Simone C
Med Hypotheses; 1999 Jul; 53(1):50-62. PubMed ID: 10499826
[TBL] [Abstract][Full Text] [Related]
11. New kids in the block: the role of FasL and Fas in kidney damage.
Ortiz A; Lorz C; Egido J
J Nephrol; 1999; 12(3):150-8. PubMed ID: 10440512
[TBL] [Abstract][Full Text] [Related]
12. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
[TBL] [Abstract][Full Text] [Related]
13. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
15. [FasL-Fas/APO-1 (CD95) system].
Sun CK; Ju G
Sheng Li Ke Xue Jin Zhan; 1997 Apr; 28(2):136-8. PubMed ID: 11038707
[No Abstract] [Full Text] [Related]
16. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
17. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
18. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
20. Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells.
Ahmad R; Menezes J; Knafo L; Ahmad A
J Leukoc Biol; 2001 Jan; 69(1):123-8. PubMed ID: 11200056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
